•	•				×0						· 14	
Substitute form 1449A/PTO							Complete if Known			<u> </u>		\leftarrow_{\succ}
						u/	Application Number 09/525,797		-	180%	-√	-
INFORMATION DISCLOSURE つ。							Filing Date	15 March 2000		1/	کر د	<u> </u>
STATEMENT BY APPLICANT & S						ဂ်/ ၂	First Named Inventor	Athanasius A. Anagnostou			1/2	· 65
₩ ₩					Group Art Unit	1642			150	_~0		
(use as ma	any she	ets as n	necessary) 🖏	a -		'	Examiner Name	S. Ungar				600
Sheet	1		of 1	ARCOI			Attorney Docket Number	5218.39B				92
U.S. PATENT DOCUMENTS												
Examiner Cite		o. U.S. Patent Document			. N		ame of Patentee or Applicant	Date of Publication of		Pages, (Columns,	Lines,
Initials*		-	Number	Kind C	ode	ĺ	of Cited Document	Cited Documer		Where Re	plevant Pa	ssages
				(if knov	wn)			MM-DD-YYYY			or Relevant Figures Appear	
gu	<u>~ 1 </u>		,745,099			Ak	camatsu et al.	5/17/88				
	2		,635,160			St	utts, et al.	3/6/97	3/6/97			
	ļ					<u> </u>						
	 					L						
	 		· · · · · · · · · · · · · · · · · · ·									
	<u> </u>							<u> </u>				
Eversions	FOREIGN PATENT DOCUMENTS Examiner Cite Foreign Patent Document Name of Patentee or Date of Publication Pages, Columns, Lines, T											
Examiner Initials*	Cite No.			Docume			Name of Patentee or Applicant of Cited	Date of Publication of Cited Document	Pa	ges, Column Where Rek	ıs, Lines, evant	1
	}	Office	Office Number		Kind Co		Document	MM-DD-YYYY		Passages or Relevant		
	 	 	+		(if knov	v(1)			 	Figures Ap	pear	+-
		 -			•		<u> </u>	· · · · · · · · · · · · · · · · · · ·	-			
	 	+	 						+			+
		 							┼			┪
· · · · · · · · · · · · · · · · · · ·			OTHER F	RIOR	ART -	NO	N PATENT LITERATURE	DOCUMENTS	٠			٠
Examiner	Cite	Include	name of the author	(in CAPI	TAL LET	TER:	S), title of the article (when appropri	tate), title of the item (bo	ok, mad	azine. jour	nal.	F
Initials*	No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published										
Sey	3	Anagnostou et al., Erythropoietin Has a Mitogenic and Positive Chemotactic Effect on Endothelial Cells, Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 5978-5982 (1990)										
	4	Cao	et al arma a-C-	Y-C-C	emoki	<u>. PP</u>	ls an Angiogenesis Inhihitor	That Sunnmenn	tha G	mudb of		
- 1] "		Cao, et al., gro-s, a-C-X-C-Chemokine Is an Angiogenesis Inhibitor That Suppresses the Growth of Lewis Lung Carcinoma in Mice, J. Exp. Med., Vol. 182, 2069 (1995)									
	5	Carlini et al., Effect of Recombinant Human Erythropoietin (rHuEPO) on Apoptosis in Endothelial Cells,										
	6	J. Amer. Society Nephrology, Vol. 7, No. 9, pg. 1559; Abstract A1548 (1996) Carlini, et al., Recombinant Human Erythropoietin Stimulates Anglogenesis, Kidney International, Vol.										
		47, pp. 740-745 (1995)										
.	7	Cazzola, M., Erythropoietin: biology and clinical applications. Trends in Experimental and Clinical										
	8	Hand	Medicine, Vol. 3, pp. 344-361 (1993) Hand, et al., Erythropoietin Enhances Vascular Responsiveness to Norepinephrine in Renal Failure,									
		Kidney International, Vol. 48, pp. 806-813 (1995)										
	<u>-9</u>	International Search-Report for PCT/US97/15966										
82	10	Kumar, et al, Basic Pathology, W. B. Saunders Company, Philadelphia, pg. 194 (1992)										
1	11	Kuriyama et al., Evidence for Amelioration of Endothelial Cell Dysfunction by Erythropoletin Therapy in									$\neg \neg$	
		Predic	<u>alysis Patents, A</u>	<u>m. J. F</u>	lyperte	<u>n. V</u>	ol. 9, No. 5, pp. 426-431 (*	1996)			<u> </u>	
- 11	12	Kuwata, et al., Treatment of Metastatic Liver Tumors by Intermittent Repetitive Injection of an Angiogenesis Inhibitor Using an Implantable Port System in a Rabbit Model, Kobe J. Med. Sci., Vol. 43,									1	
		No 2	ngenesis innibitol 1, pp. 83-98 (199)	∵∪sing 7\	an Imp	vian	table Port System in a Rab	bit Model, Kobe J.	Med.	<u>ડલ</u> ., Vol.	43,	j
	13				ricn, of	F o E	Protoin Harmona by a Ponti	do Agonist: The El	20.0			
		Livnah, et al., Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 Å, Science, Vol. 273, pp. 464-471 (1996)								ŀ		
	14	Maier	et al In vitro in	hibition	of en	doth	pelial cell growth by the anti	angiogenic daya AC	2M-14	TO THE		
		Maler, et al., In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11, Anti-Cancer Drugs, Vol. 8, pp. 238 (1997)										
	15	Markham, et al., Epoetin Alfa, A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Nonrenal Applications, Drugs, Vol. 49, No. 2, pp. 232-254 (1995)										
	16	Nagai, et al., Effects of rHuEpo on Cellular Proliferation and Endothelin-1 Production in Cultured										
	47	Endot	Endothelial Cells, Nephrol Dial Transplant, Vol. 10, pp. 1814-1819 (1995)									
	17	Strate	Pluda, J.M., Tumor-Associated Angiogenesis: Mechanisms, Clinical Implications, and Therapeutic Strategies, Seminars in Oncology, Vol. 24, pp. 203 (1997)									1
	18	Takan	Takano, et al., A Diaminoathraquinone Inhibitor of Angiogenesis, J. Pharmacol, Exp. Ther., Vol. 271,									
	19	Wrigh	pg. 1027 (1994) Wrighton, et al., Small Peptides as Potent Mimetics of the Protein Hormone Erythropoletin, Science,									
	20	Vol. 2	Vol. 273, pp. 458-463 (1996)									
		Europ	Yamaji et al., Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA, European J. Biochem., Vol. 239, pp. 494-500 (1996)									
	21	Yamaji, et al., Brain Capillary Endothelial Cells Express Two Forms of Erythropoletin Receptor mRNA,										

Examiner Signature	. , ,	•	Date Considered	
			Date Considered	1 . 172 / 1
	1 11	1		1 17162101
		1481		[20.0
*EXAMINER: Initial if ref	erence conside	atéd whether or not citation is	in conformance with MDED 600	Drove line Absourch wit-sing if

TEAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.